These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 20166103)

  • 21. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer.
    Chan JM; Stampfer MJ; Ma J; Gann P; Gaziano JM; Pollak M; Giovannucci E
    J Natl Cancer Inst; 2002 Jul; 94(14):1099-106. PubMed ID: 12122101
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Insulin-like growth factor-I and -II in human benign prostatic hyperplasia: relationship with binding proteins 2 and 3 and androgens.
    Monti S; Di Silverio F; Lanzara S; Varasano P; Martini C; Tosti-Croce C; Sciarra F
    Steroids; 1998; 63(5-6):362-6. PubMed ID: 9618803
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era.
    Platz EA; Leitzmann MF; Rifai N; Kantoff PW; Chen YC; Stampfer MJ; Willett WC; Giovannucci E
    Cancer Epidemiol Biomarkers Prev; 2005 May; 14(5):1262-9. PubMed ID: 15894683
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum androgens and prostate cancer.
    Nomura AM; Stemmermann GN; Chyou PH; Henderson BE; Stanczyk FZ
    Cancer Epidemiol Biomarkers Prev; 1996 Aug; 5(8):621-5. PubMed ID: 8824364
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Regional variations of insulin-like growth factor I (IGF-I), IGF-II, and receptor type I in benign prostatic hyperplasia tissue and their correlation with intraprostatic androgens.
    Monti S; Di Silverio F; Iraci R; Martini C; Lanzara S; Falasca P; Poggi M; Stigliano A; Sciarra F; Toscano V
    J Clin Endocrinol Metab; 2001 Apr; 86(4):1700-6. PubMed ID: 11297606
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prostate carcinoma incidence in relation to prediagnostic circulating levels of insulin-like growth factor I, insulin-like growth factor binding protein 3, and insulin.
    Chen C; Lewis SK; Voigt L; Fitzpatrick A; Plymate SR; Weiss NS
    Cancer; 2005 Jan; 103(1):76-84. PubMed ID: 15540247
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer.
    Harman SM; Metter EJ; Blackman MR; Landis PK; Carter HB;
    J Clin Endocrinol Metab; 2000 Nov; 85(11):4258-65. PubMed ID: 11095464
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vitamin D receptor gene polymorphisms, insulin-like growth factors, and prostate cancer risk: a population-based case-control study in China.
    Chokkalingam AP; McGlynn KA; Gao YT; Pollak M; Deng J; Sesterhenn IA; Mostofi FK; Fraumeni JF; Hsing AW
    Cancer Res; 2001 Jun; 61(11):4333-6. PubMed ID: 11389055
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Circulating Insulin-Like Growth Factor 1-Related Biomarkers and Risk of Lethal Prostate Cancer.
    Ma C; Wang Y; Wilson KM; Mucci LA; Stampfer MJ; Pollak M; Penney KL
    JNCI Cancer Spectr; 2022 Feb; 6(1):. PubMed ID: 35047751
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Androgens in serum and the risk of prostate cancer: a nested case-control study from the Janus serum bank in Norway.
    Vatten LJ; Ursin G; Ross RK; Stanczyk FZ; Lobo RA; Harvei S; Jellum E
    Cancer Epidemiol Biomarkers Prev; 1997 Nov; 6(11):967-9. PubMed ID: 9367072
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Insulin-like growth factor I (IGF-I), IGF-binding proteins, and breast cancer.
    Krajcik RA; Borofsky ND; Massardo S; Orentreich N
    Cancer Epidemiol Biomarkers Prev; 2002 Dec; 11(12):1566-73. PubMed ID: 12496045
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Circulating insulin-like growth factor-I, total and free testosterone concentrations and prostate cancer risk in 200 000 men in UK Biobank.
    Watts EL; Fensom GK; Smith Byrne K; Perez-Cornago A; Allen NE; Knuppel A; Gunter MJ; Holmes MV; Martin RM; Murphy N; Tsilidis KK; Yeap BB; Key TJ; Travis RC
    Int J Cancer; 2021 May; 148(9):2274-2288. PubMed ID: 33252839
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Circulating insulin-like growth factor-I and binding protein-3 and risk of prostate cancer.
    Severi G; Morris HA; MacInnis RJ; English DR; Tilley WD; Hopper JL; Boyle P; Giles GG
    Cancer Epidemiol Biomarkers Prev; 2006 Jun; 15(6):1137-41. PubMed ID: 16775172
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Androgens and prostate cancer risk: a prospective study.
    Wirén S; Stocks T; Rinaldi S; Hallmans G; Bergh A; Stenman UH; Kaaks R; Stattin P
    Prostate; 2007 Aug; 67(11):1230-7. PubMed ID: 17562541
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of gender and androgen status on IGF-I levels in normal and GH-deficient adults.
    Fisker S; Jorgensen JO; Vahl N; Orskov H; Christiansen JS
    Eur J Endocrinol; 1999 Dec; 141(6):601-8. PubMed ID: 10601963
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Circulating insulin-like growth factors and risks of overall, aggressive and early-onset prostate cancer: a collaborative analysis of 20 prospective studies and Mendelian randomization analysis.
    Watts EL; Perez-Cornago A; Fensom GK; Smith-Byrne K; Noor U; Andrews CD; Gunter MJ; Holmes MV; Martin RM; Tsilidis KK; Albanes D; Barricarte A; Bueno-de-Mesquita HB; Cohn BA; Deschasaux-Tanguy M; Dimou NL; Ferrucci L; Flicker L; Freedman ND; Giles GG; Giovannucci EL; Haiman CA; Hankey GJ; Holly JMP; Huang J; Huang WY; Hurwitz LM; Kaaks R; Kubo T; Le Marchand L; MacInnis RJ; Männistö S; Metter EJ; Mikami K; Mucci LA; Olsen AW; Ozasa K; Palli D; Penney KL; Platz EA; Pollak MN; Roobol MJ; Schaefer CA; Schenk JM; Stattin P; Tamakoshi A; Thysell E; Tsai CJ; Touvier M; Van Den Eeden SK; Weiderpass E; Weinstein SJ; Wilkens LR; Yeap BB; ; Allen NE; Key TJ; Travis RC
    Int J Epidemiol; 2023 Feb; 52(1):71-86. PubMed ID: 35726641
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of finasteride on serum levels of androstenedione, testosterone and their 5α-reduced metabolites in men at risk for prostate cancer.
    Stanczyk FZ; Azen CG; Pike MC
    J Steroid Biochem Mol Biol; 2013 Nov; 138():10-6. PubMed ID: 23474436
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of serum retinol and carotenoids with insulin-like growth factors and insulin-like growth factor binding protein-3 among control subjects of a nested case-control study in the Japan Collaborative Cohort Study.
    Suzuki K; Ito Y; Hashimoto S; Kawado M; Inoue T; Ando M; Watanabe Y; Inaba Y; Tajima K; Nakachi K; Tamakoshi A;
    Asian Pac J Cancer Prev; 2009 Dec; 10 Suppl():29-35. PubMed ID: 20553078
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis.
    Yu H; Spitz MR; Mistry J; Gu J; Hong WK; Wu X
    J Natl Cancer Inst; 1999 Jan; 91(2):151-6. PubMed ID: 9923856
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prostate-specific antigen, sex steroid hormones, and the insulin-like growth factor axis in U.S.-born, Jamaican, and Haitian black men: a pilot study.
    Chen AC; MacChia RJ; Conway F; Magai C; Desai M; Neugut AI
    Urology; 2004 Sep; 64(3):522-7. PubMed ID: 15351583
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.